{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:52:07Z","timestamp":1782309127119,"version":"3.54.5"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.tem.2015.01.007","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T16:40:10Z","timestamp":1424450410000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Emerging cardiovascular indications of mineralocorticoid receptor antagonists"],"prefix":"10.1016","volume":"26","author":[{"given":"Yasir","family":"Parviz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Al-Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2015.01.007_bib0525","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.tem.2015.01.007_bib0530","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.tem.2015.01.007_bib0535","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0540","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0545","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2015.01.007_bib0550","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0375","doi-asserted-by":"crossref","first-page":"e111104","DOI":"10.1371\/journal.pone.0111104","article-title":"Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade","volume":"9","author":"Martin-Fernandez","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tem.2015.01.007_bib0555","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0560","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0565","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0570","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0575","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0580","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2010.06.049","article-title":"Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial","volume":"160","author":"Beygui","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00129784-200505010-00007","article-title":"Eplerenone: a review of its use in essential hypertension","volume":"5","author":"Croom","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.tem.2015.01.007_bib0590","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.tem.2015.01.007_bib0595","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2015.01.007_bib0600","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0605","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","article-title":"Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension","volume":"163","author":"Hollenberg","year":"2003","journal-title":"Arch. Internal Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0610","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0615","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.tem.2015.01.007_bib0620","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08037050701461084","article-title":"2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"16","author":"Mansia","year":"2007","journal-title":"Blood Press"},{"key":"10.1016\/j.tem.2015.01.007_bib0625","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0630","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0635","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction","volume":"1","author":"Patel","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0640","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.tem.2015.01.007_bib0645","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","volume":"12","author":"Edelmann","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0650","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0655","first-page":"33","article-title":"[Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension]","volume":"70","author":"Martyniuk","year":"1998","journal-title":"Ter. Arkh."},{"key":"10.1016\/j.tem.2015.01.007_bib0660","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/hr.2010.16","article-title":"Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension","volume":"33","author":"Yamanaka","year":"2010","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.tem.2015.01.007_bib0665","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2015.01.007_bib0670","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)","volume":"112","author":"Maron","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0675","first-page":"114","article-title":"[Study on expression of mineralocorticoid receptor in human atria during atrial fibrillation]","volume":"35","author":"Pei","year":"2007","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.tem.2015.01.007_bib0680","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2015.01.007_bib0685","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0690","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0002-9149(01)01905-1","article-title":"Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation","volume":"88","author":"Goette","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0695","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0700","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00029330-200801010-00008","article-title":"Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs","volume":"121","author":"Yang","year":"2008","journal-title":"Chinese Med. J."},{"key":"10.1016\/j.tem.2015.01.007_bib0705","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1476-5381.2009.00551.x","article-title":"Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing","volume":"159","author":"Zhao","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tem.2015.01.007_bib0710","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","article-title":"Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure","volume":"17","author":"Shroff","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0715","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/clc.20914","article-title":"Effect of spironolactone on patients with atrial fibrillation and structural heart disease","volume":"34","author":"Williams","year":"2011","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0720","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.amjcard.2012.12.020","article-title":"Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation","volume":"111","author":"Ito","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0725","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0730","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.amjcard.2010.07.037","article-title":"Effect of combined spironolactone-beta-blocker +\/\u2212 enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study)","volume":"106","author":"Dabrowski","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0380","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2015.01.007_bib0735","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/clc.20762","article-title":"The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis","volume":"33","author":"Wei","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0740","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000049089","article-title":"Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction","volume":"96","author":"Beck","year":"2001","journal-title":"Cardiology"},{"key":"10.1016\/j.tem.2015.01.007_bib0385","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.tem.2015.01.007_bib0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.tem.2015.01.007_bib0395","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0400","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0405","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tem.2015.01.007_bib0410","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2013.09.057","article-title":"Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis","volume":"63","author":"Pitt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0415","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2015.01.007_bib0420","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1096\/fj.13-245415","article-title":"Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice","volume":"28","author":"Armani","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2015.01.007_bib0425","doi-asserted-by":"crossref","first-page":"685238","DOI":"10.4061\/2011\/685238","article-title":"Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome","volume":"2011","author":"Stiefel","year":"2011","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.tem.2015.01.007_bib0430","doi-asserted-by":"crossref","first-page":"e000018","DOI":"10.1161\/JAHA.112.000018","article-title":"Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism","volume":"2","author":"McGraw","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.tem.2015.01.007_bib0435","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cjca.2012.04.014","article-title":"Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque","volume":"28","author":"de Rita","year":"2012","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0440","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0445","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2015.01.007_bib0450","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension","volume":"324","author":"Alderman","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2015.01.007_bib0455","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.tem.2015.01.007_bib0460","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","article-title":"Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries","volume":"104","author":"Ward","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2015.01.007_bib0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tem.2015.01.007_bib0470","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"Kursaklioglu","year":"2004","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.tem.2015.01.007_bib0475","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijcard.2005.03.078","article-title":"Eplerenone suppresses neointimal formation after coronary stent implantation in swine","volume":"107","author":"Wakabayashi","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0480","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1210\/en.2012-1481","article-title":"Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice","volume":"153","author":"Iqbal","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2015.01.007_bib0485","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ejhf.88","article-title":"Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.tem.2015.01.007_bib0490","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2008.03.012","article-title":"A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis","volume":"156","author":"Stewart","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.tem.2015.01.007_bib0495","first-page":"478","article-title":"Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation","volume":"21","author":"Zendaoui","year":"2012","journal-title":"J. Heart Valve Disease"},{"key":"10.1016\/j.tem.2015.01.007_bib0500","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2015.01.007_bib0505","doi-asserted-by":"crossref","first-page":"R944","DOI":"10.1152\/ajpregu.2001.281.3.R944","article-title":"Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats","volume":"281","author":"Dorrance","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Compar. Physiol."},{"key":"10.1016\/j.tem.2015.01.007_bib0510","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2007.03.043","article-title":"Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model","volume":"566","author":"Iwanami","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tem.2015.01.007_bib0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/STROKEAHA.110.598441","article-title":"Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia","volume":"42","author":"Frieler","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.tem.2015.01.007_bib0520","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur. Heart J."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276015000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276015000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T09:44:44Z","timestamp":1717753484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276015000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1043276015000223"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2015.01.007","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging cardiovascular indications of mineralocorticoid receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2015.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}